The development of new antimicrobials to combat bacterial resistance is an urgent need given the increasing presence of multidrug-resistant organisms, an important concern especially for vulnerable individuals.
Synthetic, multi-epitope peptide vaccines are becoming an attractive universal influenza vaccine strategy. Longhorn Vaccines & Diagnostics LLC has created LHNVD-105, an influenza vaccine candidate consisting of unconjugated multi-epitope influenza peptides.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding $1.75 million to the University of Melbourne at the Peter Doherty Institute for Infection and Immunity to develop an oral therapeutic that restores the activity of common antibiotics used to treat community-acquired bacterial pneumonia (CABP).
Redhill Biopharma Ltd. has announced a survival benefit with its oral sphingosine kinase-2 (SPHK2) selective inhibitor opaganib (ABC-294640) in an in vivo Ebola virus study.
Ocean Biomedical Inc. has demonstrated the effectiveness of its anti-chitinase 3-like-1 (CHI3L1) antibody in suppressing and reversing tumor growth in studies of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) cells.
Atomwise Inc. has nominated a development candidate focused on TYK2 inhibition, discovered by leveraging its proprietary artificial intelligence (AI) drug discovery platform, Atomnet.
Researchers from East China Normal University and Shanghai Jiao Tong University presented the discovery and preclinical evaluation of new potent antiosteoporosis agents. Synthesis and optimization of a series of heterocyclic ring-fused derivatives of 20(S)-protopanaxadiol (PPD) led to the identification of SH-491 as the lead candidate with the most potent inhibitory effects on RANKL-induced osteoclastogenesis (IC50=11.8 nM).
Quantum dots, a phenomenon in quantum physics that alters the energy of electrons and changes the properties of particles, caught the attention of the Royal Swedish Academy of Sciences (KVA) for the 2023 Nobel Prize in Chemistry. Alexei Ekimov and Louis Brus received the award for their discovery; Moungi Bawendi, for developing its applications. With their work, “in equal shares,” said the Secretary General of KVA Hans Ellegren, the three scientists have laid the foundations of nanotechnology, a tool that we see today in our homes, on televisions and LED lamps, or in laboratories and hospitals for designing new drugs or new strategies against cancer.
Chiesi Farmaceutici SpA has described amido cyclopropyl derivatives acting as lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Sorrento Therapeutics Inc. has divulged antibody-drug conjugates comprising antibodies targeting HER2 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer.
RSS
